

Po-Yau Hsu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5002114/publications.pdf>

Version: 2024-02-01

24
papers

213
citations

1162367

8
h-index

1125271

13
g-index

24
all docs

24
docs citations

24
times ranked

227
citing authors

#	ARTICLE	IF	CITATIONS
1	Scaling up the in-hospital hepatitis C virus care cascade in Taiwan. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 136-143.	4.5	32
2	Establishment of an outreach, grouping healthcare system to achieve microelimination of HCV for uremic patients in haemodialysis centres (ERASE-C). <i>Gut</i> , 2021, 70, 2349-2358.	6.1	25
3	First-in-Asian double-blind randomized trial to assess the efficacy and safety of insulin sensitizer in nonalcoholic steatohepatitis patients. <i>Hepatology International</i> , 2021, 15, 1136-1147.	1.9	23
4	Role of hepatitis D virus infection in development of hepatocellular carcinoma among chronic hepatitis B patients treated with nucleotide/nucleoside analogues. <i>Scientific Reports</i> , 2021, 11, 8184.	1.6	17
5	Early Fibrosis but Late Tumor Stage and Worse Outcomes in Hepatocellular Carcinoma Patients Without Hepatitis B or Hepatitis C. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2120-2129.	1.1	13
6	Changing epidemiology and viral interplay of hepatitis B, C and D among injecting drug user-dominant prisoners in Taiwan. <i>Scientific Reports</i> , 2021, 11, 8554.	1.6	11
7	Significant amelioration of hepatitis C virus infection in a hyperendemic area: longitudinal evidence from the COMPACT Study in Taiwan. <i>BMJ Open</i> , 2021, 11, e042861.	0.8	10
8	Outreach onsite treatment with a simplified pangenotypic direct-acting anti-viral regimen for hepatitis C virus micro-elimination in a prison. <i>World Journal of Gastroenterology</i> , 2022, 28, 263-274.	1.4	10
9	Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 186-196.	4.5	9
10	Serial serologic changes of hepatitis D virus in chronic hepatitis B patients receiving nucleos(t)ides analogues therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1886-1892.	1.4	8
11	Role of hepatitis D virus in persistent alanine aminotransferase abnormality among chronic hepatitis B patients treated with nucleotide/nucleoside analogues. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 303-310.	0.8	8
12	Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha-fetoprotein levels. <i>Cancer Medicine</i> , 2022, 11, 104-116.	1.3	7
13	Genotype distribution, clinical characteristics, and racial differences observed in chronic hepatitis C patients in Pingtung, Taiwan. <i>Journal of the Chinese Medical Association</i> , 2021, 84, 255-260.	0.6	6
14	Dynamics of cytokines predicts risk of hepatocellular carcinoma among chronic hepatitis C patients after viral eradication. <i>World Journal of Gastroenterology</i> , 2022, 28, 140-153.	1.4	6
15	Concordance of SVR12, SVR24 and SVR durability in Taiwanese chronic hepatitis C patients with direct-acting antivirals. <i>PLoS ONE</i> , 2021, 16, e0245479.	1.1	5
16	Evolutionary seroepidemiology of viral hepatitis and the gap in hepatitis C care cascades among uraemic patients receiving haemodialysis in Taiwan—the Formosa-Like Group. <i>Journal of Viral Hepatitis</i> , 2021, 28, 719-727.	1.0	5
17	The applicability of non-invasive methods for assessing liver fibrosis in hemodialysis patients with chronic hepatitis C. <i>PLoS ONE</i> , 2020, 15, e0242601.	1.1	5
18	Towards a safe hospital: hepatitis C in-hospital micro-elimination program (HCV-HELP study). <i>Hepatology International</i> , 2022, 16, 59-67.	1.9	5

#	ARTICLE	IF	CITATIONS
19	Comorbidities in patients with chronic hepatitis C and hepatitis B on hemodialysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2261-2269.	1.4	2
20	Serum <i>Wisteria floribunda</i> agglutinin-positive Mac-2-binding protein expression predicts disease severity in nonalcoholic steatohepatitis patients. <i>Kaohsiung Journal of Medical Sciences</i> , 2022, 38, 261-267.	0.8	2
21	Itemization difference of patient-reported outcome in patients with chronic liver disease. <i>PLoS ONE</i> , 2022, 17, e0264348.	1.1	2
22	Low disease awareness as a contributing factor to the high prevalence of hepatitis C infection in Tzukuan, a hyperendemic area of southern Taiwan. <i>Kaohsiung Journal of Medical Sciences</i> , 2022, , .	0.8	2
23	Hypopharyngeal and Laryngeal Lesions in a Patient with Chickenpox. <i>Ear, Nose and Throat Journal</i> , 2020, 100, 014556132093231.	0.4	0
24	Seroreversion of hepatitis B surface antigen among subjects with resolved hepatitis B virus infection: A community-based cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 3239-3246.	1.4	0